May 4, 2020
The Altman Clinical and Translational Research Institute at University of California San Diego has received a five-year, $54.7 million Clinical and Translational Science Award from the National Center for Advancing Translational Science (NCATS), part of the National Institutes of Health.
February 2, 2015
The governing board of the California Institute for Regenerative Medicine (CIRM) has awarded two University of California, San Diego researchers almost $3 million in combined funding to pursue new technologies intended to accelerate advances moving stem cell therapies out of the lab and into the clinic.
November 16, 2016
…with moderate to severe Crohn’s disease. Results of the clinical trial will appear in the November 16 issue of the New England Journal of Medicine.
April 9, 2013
As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma (HCC) or liver cancer. Pexa-Vec is a genetically engineered virus that is used in the smallpox vaccine.
June 3, 2021
As the first designated medical center in San Diego certified to offer this type of immunotherapy, UC San Diego Health will begin treating patients this month.
May 12, 2016
…of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia.
December 6, 2021
UC San Diego School of Medicine partners with The Michael J. Fox Foundation on a clinical study to identify biomarkers of Parkinson’s disease. The study seeks to recruit 4,000 participants by the end of 2023.
November 24, 2021
The California Institute for Regenerative Medicine (CIRM) approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.
September 17, 2015
More than five million Americans are living with Alzheimer’s disease (AD). Of them, 400,000 also have Down syndrome. Both groups have similar looking brains with higher levels of the protein beta amyloid. In fact, patients with Down syndrome develop the abnormal protein at twice the rate. Results of a pilot…
November 12, 2021
…the randomized, double-blind, placebo-controlled clinical trial. Three trials are currently recruiting for between 66 and 80 patients who have tested positive for SARS-CoV-2 and who are quarantined at home with mild to moderate symptoms. Two are Food and Drug Administration (FDA)-approved Phase 1 clinical safety trials for investigational compounds to…
